<DOC>
	<DOC>NCT03062540</DOC>
	<brief_summary>This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)—a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible patients will have a telephonic visit at week 2 and then return regularly to the study clinic for monthly visits for assessments of efficacy and safety.</brief_summary>
	<brief_title>Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD</brief_title>
	<detailed_description />
	<mesh_term>Cyclobenzaprine</mesh_term>
	<criteria>Male or female between 18 and 75 years of age, who have served in any branch of the military. Diagnosed with current PTSD as determined by the ClinicianAdministered PTSD Scale (CAPS5) for DSM5. Index trauma(s) resulting in PTSD must meet DSM5 criterion A for PTSD as described in CAPS5, have occurred in 2001 or later, be military service related. Willing to refrain from use of all other formulations of cyclobenzaprine. Willing and able to refrain from antidepressants and other excluded medications. Capable of reading and understanding English and able to provide written informed consent. If female, either not of childbearing potential or practicing a medically acceptable method of birth control throughout the study. Willing and able to comply with all protocolspecified requirements. Increased risk of suicide, based on the investigator's judgment that is of a severity that is not appropriate for outpatient management, or that warrants additional therapy excluded by the protocol. Significant (e.g., moderate or severe) comorbid traumatic brain injury (TBI) by history. Severe depressive symptoms at screening or baseline based on a score ≥29 on the BDIII at Visits 1 or 2. Clinically significant laboratory abnormalities based on screening laboratory tests and/or medical history in the investigator's opinion. Use of antidepressant medication within 2 months of baseline. Female patients who are pregnant or lactating. History of serotonin syndrome, severe allergic reaction or bronchospasm or known hypersensitivity to cyclobenzaprine or the excipients. Seizure disorder. Patients with a body mass index (BMI) &gt; 45. Has received any other investigational drug within 30 days before Screening. Previous participation in any other study with TNX102 SL. Family member of investigative staff.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PTSD</keyword>
	<keyword>Military-related PTSD</keyword>
</DOC>